Apogee Therapeutics, Inc.
corporate_fare Company Profile
Apogee Therapeutics, Inc. (NASDAQ:APGE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for APGE at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Apogee Secures $403M Equity Raise, Extends Runway to 2029, Advances Lead Drug to Phase 3
- $377.4M Equity Offering Finalized by Apogee Therapeutics, Underwriters Exercise Full Option
- Apogee Therapeutics Finalizes $402.5M Public Offering at $70.00/Share
- Apogee Therapeutics Prices $350M Public Offering at $70.00/Share Following Positive Clinical Data
- Apogee Therapeutics Prices $350M Offering at $70/Share Following Positive Trial Data
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$255.84M
Diluted EPS
-$4.22
Op. Cash Flow
-$227.45M
Free Cash Flow
-$232.6M
Operating Income
-$285.6M
Cash & Equivalents
$131.55M
Shares Outstanding
68.4M sh
Source: 10-K · filed 2026-03-02 · accession 0001974640-26-000002
feed APGE - Filings & News (Page 2)
APGE
May 11, 2026, 7:00 AM EDT
APGE
Mar 25, 2026, 4:53 PM EDT
APGE
Mar 25, 2026, 4:44 PM EDT
APGE
Mar 25, 2026, 4:40 PM EDT
APGE
Mar 24, 2026, 9:54 PM EDT
APGE
Mar 23, 2026, 4:28 PM EDT
APGE
Mar 23, 2026, 4:01 PM EDT
APGE
Mar 23, 2026, 6:36 AM EDT
APGE
Mar 23, 2026, 6:30 AM EDT
APGE
Mar 02, 2026, 7:25 AM EST
APGE
Mar 02, 2026, 7:20 AM EST
APGE
Mar 02, 2026, 7:15 AM EST
APGE
Feb 11, 2026, 10:42 AM EST
APGE
Jan 22, 2026, 8:07 PM EST
APGE
Jan 22, 2026, 8:03 PM EST
APGE
Jan 22, 2026, 8:00 PM EST